AngioDynamics (ANGO) reports Q4 2026 earnings with 8% revenue growth and strategic initiatives driving future profitability.

Key Takeaways

• Revenue increased by 8% to $86.6 million in Q4 2026, driven by MedTech growth.
• MedTech revenue reached $41.8 million, a 16.7% increase year-over-year.
• Net loss for Q4 was $11.4 million, translating to a loss per share of $0.27, compared to a loss of $6.1 million or $0.15 per share a year ago.
• Total revenue for FY2026 increased by 9.4% to $320.2 million, with MedTech revenue up 18.4% to $150 million.
• Fiscal 2027 guidance anticipates net sales between $336 million and $341 million, representing growth of 5% to 6.5%.

Financial Performance

AngioDynamics, Inc. reported a strong financial performance for the fourth quarter of fiscal year 2026. The company achieved a total revenue of $86.6 million, marking an 8% increase compared to the same quarter last year. This growth was bolstered by the MedTech segment which generated $41.8 million in revenue, reflecting a significant 16.7% year-over-year increase.

For the entire fiscal year 2026, total revenue reached $320.2 million, representing a 9.4% growth as the company continues to gain traction in competitive markets. While the company reported a net loss of $36.7 million for the full year, this was an improvement from the previous year’s loss of $34 million. The adjusted net loss for Q4 was $2.8 million, indicating the company is working towards profitability despite external challenges such as tariffs.

Strategic Initiatives

AngioDynamics has been focusing on strategic growth through its innovative MedTech portfolio. The company’s Airiane platform achieved its 20th consecutive quarter of double-digit growth, contributing $17.8 million in revenue, up 14.4% year-over-year. The strong performance is supported by a shift towards hospital care and increased international adoption.

The mechanical thrombectomy segment, which includes products like AngioVac and AlphaVac, saw overall growth, although there was a 1.1% year-over-year decline in mechanical thrombectomy revenue for the quarter. Notably, AlphaVac revenue surged by 38.4%, showcasing its strong market demand. The company is also optimistic about upcoming catalysts such as the Alpha Return Blood Management system, which has received IDE approval and is undergoing pivotal trials.

Additionally, the NanoKnife product line demonstrated exceptional performance with 64.5% revenue growth for the fiscal year. The increased physician interest in prostate procedures is expected to drive further growth, particularly after the recent Medicare coverage approval. Management emphasized the importance of generating high-quality clinical data to bolster market adoption and expand treatment indications.

Future Outlook

Looking ahead, AngioDynamics has set a fiscal 2027 guidance that projects net sales between $336 million and $341 million, reflecting a growth rate of 5% to 6.5%. The company expects its MedTech segment to continue its strong performance, projecting a year-over-year growth of 12% to 15%, while the med device segment is anticipated to remain roughly flat.

Management has reiterated its commitment to maintaining a 54% to 55% gross margin and is targeting an adjusted EBITDA in the range of $13 million to $16 million. Importantly, the management expects the tariff impacts to remain consistent with the previous year, allowing for better forecasting and planning.

The leadership transition is another vital aspect to monitor, as the company is currently searching for a new CEO. This transition is expected to be seamless, with current leadership committed to ensuring stability during this period.

Conclusion

In summary, AngioDynamics, Inc. has demonstrated resilience through strategic growth and a focus on profitability despite facing challenges such as tariffs and a competitive market landscape. The company’s strong performance in MedTech, particularly with the Airiane platform and NanoKnife product line, indicates a robust future outlook. As fiscal year 2027 approaches, the guidance suggests sustained growth and continued investment in innovation. Investors should keep a close watch on AngioDynamics as it navigates this transformative phase and continues to drive value for shareholders.

This analysis is based on public earnings call materials and is not investment advice.